CNTX - NASDAQ
Context Therapeutics Inc.
$2.05
-15%Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
At a Glance
Live SnapshotContext Therapeutics Inc. Management Team
Ms. Jennifer Minai-Azary
Chief Financial Officer & Treasurer
Compensation
$564,090
Mr. Alex C. Levit Esq., J.D.
Chief Legal Officer & Corporate Secretary
Compensation
$541,334
Mr. Martin A. Lehr
Co-Founder, President, Chief Executive Officer & Director
Compensation
$765,596
Dr. Karen L. Smith L.L.M., M.B.A., M.D., PH.D.
Interim Chief Medical Officer & Director
Compensation
$14,552
Mr. Christopher Beck M.B.A.
Senior Vice President of Operations
Ms. Jennifer Dashnau M.B.A., Ph.D.
Senior Vice President of Technical Operations
Context Therapeutics Inc. Insider Positioning
During the last 12 months, insiders have purchased $601K worth of CNTX shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
916.4K
601.01K
0
0.00
+601K
+$601K
Top Buyers
Pasternak Andy
Director
$91K
Walker Luke Nathaniel
Director
$81K
Smith Karen L.
Director
$81K
West Linda
Director
$81K
Stacey Jennifer Evans
Director
$81K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $601K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
CNTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 15, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | July 24, 2024 | September 17, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 06, 2023 | May 31, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 04, 2022 | June 02, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.